IFF Q3 2025 Earnings Call Summary

1Key Financial Results and Metrics

Revenue: Approximately $2.7 billion, flat year-over-year against a strong 9% comparable.

Adjusted Operating EBITDA: $519 million, a 7% increase with a margin improvement of 130 basis points to 19.3%.

Sales Growth: Year-to-date sales growth of 2% and adjusted operating EBITDA growth of 7%.

Net Debt to EBITDA: Improved to approximately 2.5x, with gross debt reduced to about $6 billion.

Free Cash Flow: Year-to-date cash flow from operations totaled $532 million, with CapEx at $406 million.

2Strategic Updates and Business Highlights

Innovation Centers: Opened new Scent and Citrus Innovation Centers in Dubai and Florida, respectively, and expanded the LMR Natural site in France.

Collaborations: Announced strategic partnerships with BASF for enzyme and polymer innovation and a joint venture with Kemira for sustainable alternatives.

Divestitures: Completed divestitures of Pharma Solutions and Nitrocellulose, and announced the sale of the Soy Crush, Concentrates & Lecithin business to Bunge.

Focus on Profitability: Continued emphasis on operational improvements in the Food Ingredients segment, achieving a 24% increase in adjusted operating EBITDA.

3Forward Guidance and Outlook

Full-Year Guidance: Reiterated expectations for 2025 sales between $10.6 billion and $10.9 billion and adjusted operating EBITDA between $2 billion and $2.15 billion.

Q4 Expectations: Anticipated seasonal decline in sales and margins, with a cautious outlook for low single-digit growth due to macroeconomic pressures.

2026 Outlook: Cautiously optimistic for growth acceleration in 2026, particularly in Health & Biosciences and Fine Fragrance segments.

4Challenges and Points of Concern

Health & Biosciences: Experiencing slowdowns in North America, with expected improvements in 2026 but ongoing uncertainty.

Food Ingredients: Sales down 3% year-over-year, primarily due to softness in Protein Solutions, though profitability has improved.

Macro Environment: Ongoing geopolitical challenges and market uncertainty impacting customer demand and inventory levels, particularly in North America.

Competitive Pressures: Need to adapt to a K-shaped economy where lower-income households are spending less, affecting overall volume growth.

5Notable Q&A Insights

Health & Biosciences: Leadership changes and increased investment in innovation are aimed at reversing the slowdown in North America, with expectations for recovery in 2026.

Top-Line Guidance: Cautious outlook for Q4 due to macroeconomic factors, with a focus on managing inventory levels.

Private Label Growth: Regional and local businesses, including private label, are growing faster than multinationals, prompting IFF to increase focus on these segments.

Fine Fragrance Growth: Strong growth driven by innovative capabilities and social media trends, though future growth rates may stabilize at solid levels rather than the current high rates.

Cost Optimization: Continued emphasis on productivity improvements and operational efficiency to maintain profitability in a challenging growth environment. Overall, IFF's Q3 2025 results reflect a company navigating a complex macroeconomic landscape while focusing on strategic investments and operational improvements to drive future growth.